LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » World News

Pfizer revenue misses as demand falls for older drugs, Prevnar

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Updated: Tue, Aug 01, 2017
06:39 pm
Reuters

Pfizer Inc`s quarterly revenue missed Wall Street estimates on Tuesday, hurt by falling demand for its blockbuster pneumonia vaccine Prevnar as well as older drugs.

Sales of Prevnar declined 8.2 percent to $1.15 billion, largely due to the timing of government purchases for the pediatric indication.

Sales of its copycat generics and biosimilars fell 13.5 percent in the quarter to $5.23 billion.

"Pfizer`s ambition of stabilizing this book of business looks some way off," Berenburg analysts said in a note.

Revenue from its patent-protected drugs rose about 8 percent to $7.67 billion in the quarter.

Sales of its key drugs, including rheumatoid arthritis treatment Xeljanz and breast cancer treatment Ibrance beat analyst estimates.

However, overall revenue fell to $12.9 billion in the second quarter from $13.15 billion, below the analysts` estimate of $13.08 billion, according to Thomson Reuters I/B/E/S.

"These results show that Pfizer`s growth drivers are still insufficient to drive meaningful sales growth against the backdrop of generic erosion," Berenberg analysts said in a note.

Net income attributable to the largest U.S. drugmaker rose to $3.07 billion, or 51 cents per share, from $2.05 billion, or 33 cents per share, a year earlier.

Excluding items, Pfizer earned 67 cents per share, beating the average analysts` estimate by a cent.

Looming patent expirations on Pfizer`s sexual dysfunction treatment Viagra, pain drug Lyrica and falling Prevnar sales has pushed analysts to prescribe deals to resuscitate the company`s growth.

"Over the next five years, we project the potential for approximately 25 to 30 approvals, of which up to 15 have the potential to be blockbusters," Chief Executive Ian Read said in a statement on Tuesday.

Last year, Pfizer acquired drugmaker Medivation for $14 billion and decided against splitting itself into two companies, one housing its patent-protected drug business and the other its generics business.

The drugmaker also narrowed its 2017 adjusted earnings forecast to a range of $2.54 per share to $2.60 per share. It had previously forecast a range of $2.50 per share to $2.60 per share.

The company`s shares were marginally down at $33.10 before the bell on Tuesday.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:

LATEST NEWS

Realme 8 5G India launch date set for April 22: Check expected price, specifications and more

Free Fire OB27 update released in India: Check how to APK download link, new map, characters and more

Delhi curfew e-pass update: How to apply for e-pass on delhi.gov.in website, timings and more

Alert! WhatsApp status flaw allows stalkers to track users online? Check all details here

COVID-19: Role played by Indian government in speeding up vaccine development, production - All you need to know

Wipro, Auto Stocks, Insurance Stocks to Quess Corp - here are top Buzzing Stocks today

Tata Metaliks has an order book of 18 months in DI Pipes: Sandeep Kumar, MD

Oppo A74 5G set to launch under Rs 20K on THIS date - Check specifications, features and more

ICSE board exams update: CICSE postpones class 10, 12 board exams amid COVID-19

CBSE class 10 promotion criteria, class 12 board exam dates and will ICSE Class 10, 12 exams be postponed?—All you need to know

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved